Pescott CP - Search Results

1

Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.

van der Linden N, van Gils CW, Pescott CP, Buter J, Vergeer MR, Groot CA. van der Linden N, et al. Among authors: pescott cp. Eur Arch Otorhinolaryngol. 2015 Aug;272(8):2007-16. doi: 10.1007/s00405-014-3106-3. Epub 2014 Jun 19. Eur Arch Otorhinolaryngol. 2015. PMID: 24943191

2

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands.

van der Linden N, Buter J, Pescott CP, Lalisang RI, de Boer JP, de Graeff A, van Herpen CM, Baatenburg de Jong RJ, Uyl-de Groot CA. van der Linden N, et al. Among authors: pescott cp. Eur Arch Otorhinolaryngol. 2016 Feb;273(2):455-64. doi: 10.1007/s00405-015-3495-y. Epub 2015 Jan 21. Eur Arch Otorhinolaryngol. 2016. PMID: 25876000 Free PMC article.

3

Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results.

van der Linden N, van Gils CW, Pescott CP, Buter J, Uyl-de Groot CA. van der Linden N, et al. Among authors: pescott cp. Eur Arch Otorhinolaryngol. 2014 Jun;271(6):1673-8. doi: 10.1007/s00405-013-2646-2. Epub 2013 Aug 2. Eur Arch Otorhinolaryngol. 2014. PMID: 23907370

4

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands.

Uyl-de Groot CA, van Rooijen EM, Punt CJA, Pescott CP. Uyl-de Groot CA, et al. Among authors: pescott cp. Health Econ Rev. 2018 Jul 17;8(1):13. doi: 10.1186/s13561-018-0197-3. Health Econ Rev. 2018. PMID: 30019286 Free PMC article. Review.

5

Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study.

Stintzing S, van Oostrum I, Pescott CP, Ronga P, Heeg B, Heinemann V. Stintzing S, et al. Among authors: pescott cp. J Med Econ. 2020 May;23(5):448-455. doi: 10.1080/13696998.2019.1709848. Epub 2020 Jan 17. J Med Econ. 2020. PMID: 31903807 Free article.

6

Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population.

Lamy FX, Batech M, Boutmy E, Ronga P, Salim S, Pescott CP. Lamy FX, et al. Among authors: pescott cp. J Comp Eff Res. 2020 Nov;9(16):1117-1129. doi: 10.2217/cer-2020-0132. Epub 2020 Oct 29. J Comp Eff Res. 2020. PMID: 33118841 Free article.

7

Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer.

Pescott CP, Boutmy E, Batech M, Ronga P, Lamy FX. Pescott CP, et al. J Comp Eff Res. 2021 Apr;10(5):353-364. doi: 10.2217/cer-2020-0232. Epub 2021 Jan 27. J Comp Eff Res. 2021. PMID: 33502247 Free article.

8

Economic Evaluation of Three Frequently Used Gonadotrophins in Assisted Reproduction Techniques in the Management of Infertility in the Netherlands.

Fragoulakis V, Pescott CP, Smeenk JM, van Santbrink EJ, Oosterhuis GJ, Broekmans FJ, Maniadakis N. Fragoulakis V, et al. Among authors: pescott cp. Appl Health Econ Health Policy. 2016 Dec;14(6):719-727. doi: 10.1007/s40258-016-0259-9. Appl Health Econ Health Policy. 2016. PMID: 27581117

9

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma.

Bullement A, Nathan P, Willis A, Amin A, Lilley C, Stapelkamp C, Hatswell A, Pescott C, Bharmal M. Bullement A, et al. Pharmacoecon Open. 2019 Sep;3(3):377-390. doi: 10.1007/s41669-018-0115-y. Pharmacoecon Open. 2019. PMID: 30680676 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters